- Home
- ICU vs AYTU Comparison
ICU vs AYTU Comparison
Compare ICU & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- AYTU
- Stock Information
- Founded
- ICU 2018
- AYTU N/A
- Country
- ICU United States
- AYTU United States
- Employees
- ICU N/A
- AYTU N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- AYTU Health Care
- Exchange
- ICU Nasdaq
- AYTU Nasdaq
- Market Cap
- ICU 10.4M
- AYTU 8.3M
- IPO Year
- ICU N/A
- AYTU N/A
- Fundamental
- Price
- ICU $1.75
- AYTU $1.35
- Analyst Decision
- ICU
- AYTU
- Analyst Count
- ICU 0
- AYTU 0
- Target Price
- ICU N/A
- AYTU N/A
- AVG Volume (30 Days)
- ICU 24.8K
- AYTU 30.9K
- Earning Date
- ICU 04-15-2025
- AYTU 02-12-2025
- Dividend Yield
- ICU N/A
- AYTU N/A
- EPS Growth
- ICU N/A
- AYTU N/A
- EPS
- ICU N/A
- AYTU N/A
- Revenue
- ICU $68,000.00
- AYTU $77,232,000.00
- Revenue This Year
- ICU N/A
- AYTU N/A
- Revenue Next Year
- ICU $358.72
- AYTU N/A
- P/E Ratio
- ICU N/A
- AYTU N/A
- Revenue Growth
- ICU N/A
- AYTU N/A
- 52 Week Low
- ICU $1.50
- AYTU $1.30
- 52 Week High
- ICU $27.50
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- ICU 43.77
- AYTU 32.11
- Support Level
- ICU $1.71
- AYTU $1.35
- Resistance Level
- ICU $1.99
- AYTU $1.44
- Average True Range (ATR)
- ICU 0.23
- AYTU 0.10
- MACD
- ICU -0.00
- AYTU -0.02
- Stochastic Oscillator
- ICU 2.94
- AYTU 2.63
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.